Not carried
What this store does not sell, and why: 7-OH, pseudoindoxyl, MGM-15, amanita and undisclosed mushroom products
The five product classes this store refuses, each with the federal or state action behind the refusal and its date, cited to the Federal Register, FDA and CDC.
Written by: Author pendingReviewed by: Reviewer pendingUpdated:
Which five classes are refused?
Concentrated 7-hydroxymitragynine (7-OH) products; mitragynine pseudoindoxyl products; MGM-15 and MGM-16 products; Amanita muscaria and muscimol edibles; and any product, mushroom-branded or otherwise, whose active ingredient is not disclosed and quantified on a lab report. Three of the five are federal Schedule I today or are proposed to be on or after 2026-11-13 (91 FR 54948; 91 FR 65370).
Each class exists in this store's database as a regulatory class so that the checkout and the kill table can refuse it by name. A product cannot be created in one of these classes; if a supplier reclassifies an item into one, the item is archived automatically. The five are listed with the rest of the store's rules on the about page.
Why not 7-OH products?
Because the federal government has moved against them in three steps and the supply has already stopped. FDA sent seven warning letters in June and July 2025 stating that 7-OH is not an FDA-approved drug and that supplements containing it are adulterated; the letter to one marketer of 7-OH tablets and a drink mix is dated 2025-06-25 (FDA warning letter). On 2025-12-03 the Department of Justice and FDA seized about 73,000 units of 7-OH products from three Kansas City warehouses (DOJ).
The October 2026 notice of intent proposes Schedule I for 7-OH above 1 mg per gram or milliliter, or where the mitragynine-to-7-OH mass ratio is under 100, with an order possible on or after 2026-11-13 (91 FR 65370). The tablets sold under that name held 14 to 59 mg of 7-OH each and would fail both prongs; by 2026-10-13 the manufacturers had "stopped taking orders" and several brands had closed (TestMyKratom). A leaf-derived extract whose report shows 7-OH not detected is the opposite profile, which is the only kratom profile sold here.
Why not pseudoindoxyl, MGM-15 or MGM-16?
Because they are Schedule I now. The temporary order published 2026-08-26 at 91 FR 54948 placed mitragynine pseudoindoxyl, MGM-15 (dihydro-7-hydroxymitragynine) and MGM-16 (9-fluoro-dihydro-7-hydroxymitragynine), with their isomers, esters, ethers and salts, in Schedule I with no quantity threshold, effective that day and expiring 2028-08-26 unless extended (91 FR 54948).
DEA's reissued notice of 2026-10-14 keeps the no-threshold approach for the two MGM compounds (91 FR 65381). Products marketed as "OPM" or "pseudo" tablets after the 2025 actions against 7-OH used these compounds; the published lab reports for one supplier's OPM line show MGM-15 at 18 to 21 mg per tablet, which is why that line, and the supplier's pseudoindoxyl syrup and shots, will never appear here. Missouri adopted the same Schedule I designation on 2026-09-25 and has issued civil demands to distributors.
Why not Amanita muscaria or muscimol?
Because FDA has said it cannot be food. The agency's 2024-12-18 letter to industry states that Amanita muscaria, its extracts, and its constituents muscimol, ibotenic acid and muscarine do not meet the GRAS standard and are unapproved food additives, making any food containing them adulterated (FDA letter to industry). A 2025-09-11 warning letter applied that position to labeled capsules, a tincture and a chocolate bar carrying a Supplement Facts panel (FDA warning letter). Full disclosure on the label did not change the result.
Louisiana's Act 154 of 2025 makes distributing any human-consumption product containing muscimol, ibotenic acid or phenibut a felony carrying 2 to 10 years (Louisiana HB 176). The payment-monitoring vendor that card acquirers use reports amanita products at its highest risk tier "regardless of jurisdiction," singling out edibles and anything marketed as a magic mushroom alternative (LegitScript); no payment processor the research found names amanita as an accepted product, and one merchant account is underwritten to its riskiest item.
Why not mushroom chocolate bars and "mushroom tabs" sold with a psilocybin-only report?
Because that report pattern is the one regulators keep catching. FDA's investigation of one brand's chocolate bars, cones and gummies found muscimol in 9 of 22 bars, the synthetic tryptamine 4-AcO-DMT in 9 of 22 bars and 14 of 22 gummies, Schedule I psilocin in 14 of 22 gummies, the prescription drug pregabalin, and kavalactones in 18 of 22 bars; the outbreak closed at 180 illnesses, 73 hospitalizations and 3 potentially associated deaths across 34 states (FDA investigation).
CDC's test of six smoke-shop mushroom gummies found unlabeled psilocybin or psilocin in four, plus DMT, mitragynine, ephedrine and caffeine, and the testing laboratory could not even look for muscimol because it was not in its reference library (CDC MMWR 73(28)). In December 2025 California's health department found 4-AcO-DET and 4-AcO-DMT across one company's bars, syrups and gummies whose own lab reports, dated days earlier, showed no psilocin or psilocybin (KQED). A report that screens only for psilocybin and psilocin says nothing about muscimol, the 4-substituted tryptamines, kavalactones or pregabalin, because a method sees only what it is asked to see. One of this store's suppliers sells mushroom chocolate and mushroom tabs with exactly that kind of report and no disclosed active ingredient; none of it is carried.
What does the store sell instead?
Kratom extract products with a laboratory report that names the laboratory and its accreditation, quantifies mitragynine per serving and per package, and reports 7-OH with a limit of quantitation; kratom leaf under the same rule once a supplier is found; and kava with a kavalactone figure once a kava-only supplier is found. The reports and their gaps are on the lab results pages, the rules on the lab testing policy, and the federal dates on the federal scheduling timeline.
General information, not personalized guidance.
Sources
- 91 FR 54948, temporary scheduling order (August 26, 2026) Federal Register via GovInfo (accessed 2026-10-20)
- 91 FR 65370, notice of intent (October 14, 2026) Federal Register via GovInfo (accessed 2026-10-20)
- 91 FR 65381, reissued notice of intent for MGM-15 and MGM-16 (October 14, 2026) Federal Register via GovInfo (accessed 2026-10-20)
- FDA warning letter to Royal Diamond Imports Inc. (June 25, 2025) U.S. Food and Drug Administration (accessed 2026-10-20)
- Justice Department seizes unlawful 7-OH products from three warehouses (December 3, 2025) U.S. Department of Justice (accessed 2026-10-20)
- FDA letter to industry on the use of Amanita muscaria or its constituents in food (December 18, 2024) U.S. Food and Drug Administration (accessed 2026-10-20)
- FDA warning letter to Blue Forest Farms LLC (September 11, 2025) U.S. Food and Drug Administration (accessed 2026-10-20)
- Investigation of illnesses: Diamond Shruumz-brand chocolate bars, cones and gummies (June 2024) U.S. Food and Drug Administration (accessed 2026-10-20)
- CDC MMWR 73(28): mushroom gummies purchased in Virginia Centers for Disease Control and Prevention (accessed 2026-10-20)
- CDPH: do not eat this brand of magic mushroom gummies, chocolates and syrups (December 11, 2025) KQED (secondary) (accessed 2026-10-20)
- Louisiana HB 176 (2025), Act 154 Louisiana Legislature (accessed 2026-10-20)
- LegitScript: Amanita muscaria spotlight (August 11, 2023) LegitScript (accessed 2026-10-20)
- The 7-OH shortage is here (October 13, 2026) TestMyKratom (secondary) (accessed 2026-10-20)
Related questions
Is 7-OH the same thing as kratom?
No. 7-OH is 7-hydroxymitragynine, one alkaloid that DEA says makes up "less than two percent of the total alkaloid content" of the plant; products sold as "7-OH" are concentrated...
What happens on November 13, 2026?
Nothing automatically. November 13 is the earliest date DEA may publish a temporary order placing 7-hydroxymitragynine and mitragynine pseudoindoxyl above 1 mg per gram or...
What is the 1 mg per gram 7-OH threshold?
The line in DEA's October 14, 2026 notice: a product becomes a Schedule I article if it holds more than 1 mg of 7-OH or mitragynine pseudoindoxyl per gram (solid) or per...